Research & Development
New data show that European pharma innovation is being edged into third place by innovation coming from the US and the new powerhouse of research, China.
Johnson & Johnson and Roche lead the most recent Scrip 100 ranking for R&D spend, but a look beyond investment in internal development highlights a big year for Pfizer and Bristol Myer Squibb.
Novo Nordisk and Eli Lilly are duking it out in the market, but dozens of competitors are waiting in the wings.
In a post-pandemic world, the evolving landscape of clinical trials just got more complex. The year 2022 was one of many adjustments given the incidence of lower trial initiations. The health care industry endured the impacts of geopolitical conflicts, curbed growth in China and stagflation in major markets.
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.